Cascadian Therapeutics, Inc. (CASC) Now Covered by Analysts at Barclays PLC
Equities researchers at Barclays PLC initiated coverage on shares of Cascadian Therapeutics, Inc. (NASDAQ:CASC) in a report released on Wednesday, MarketBeat Ratings reports. The firm set an “underweight” rating and a $4.00 price target on the biopharmaceutical company’s stock. Barclays PLC’s target price would suggest a potential upside of 11.42% from the company’s previous close.
Several other research analysts have also commented on CASC. Cowen and Company reiterated a “buy” rating on shares of Cascadian Therapeutics in a research report on Tuesday, May 9th. Cantor Fitzgerald reiterated a “hold” rating and issued a $4.00 price target on shares of Cascadian Therapeutics in a research report on Wednesday, May 10th. Zacks Investment Research lowered Cascadian Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 19th. Finally, ValuEngine lowered Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $5.63.
Cascadian Therapeutics (CASC) traded up 1.99% during midday trading on Wednesday, hitting $3.59. The stock had a trading volume of 260,616 shares. The company’s market capitalization is $181.49 million. The stock’s 50-day moving average is $3.77 and its 200-day moving average is $3.94. Cascadian Therapeutics has a 1-year low of $3.18 and a 1-year high of $10.98.
Cascadian Therapeutics (NASDAQ:CASC) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.06. During the same period in the previous year, the business posted ($1.57) earnings per share. Equities research analysts forecast that Cascadian Therapeutics will post $5.02 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This report was posted by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/10/cascadian-therapeutics-inc-casc-now-covered-by-analysts-at-barclays-plc.html.
Hedge funds and other institutional investors have recently made changes to their positions in the business. State of Wisconsin Investment Board bought a new stake in Cascadian Therapeutics in the second quarter worth about $104,000. BlueCrest Capital Management Ltd bought a new stake in Cascadian Therapeutics in the first quarter worth about $122,000. Citadel Advisors LLC bought a new stake in Cascadian Therapeutics in the first quarter worth about $142,000. New York State Common Retirement Fund bought a new stake in Cascadian Therapeutics in the second quarter worth about $136,000. Finally, Bank of America Corp DE lifted its stake in Cascadian Therapeutics by 2,316.5% in the first quarter. Bank of America Corp DE now owns 37,528 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 35,975 shares during the last quarter. 82.55% of the stock is owned by institutional investors and hedge funds.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.